320 related articles for article (PubMed ID: 26702922)
1. What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients?
Alobaid AS; Brinkmann A; Frey OR; Roehr AC; Luque S; Grau S; Wong G; Abdul-Aziz MH; Roberts MS; Lipman J; Roberts JA
J Antimicrob Chemother; 2016 Mar; 71(3):696-702. PubMed ID: 26702922
[TBL] [Abstract][Full Text] [Related]
2. Does consistent piperacillin dosing result in consistent therapeutic concentrations in critically ill patients? A longitudinal study over an entire antibiotic course.
Carlier M; Carrette S; Stove V; Verstraete AG; De Waele JJ
Int J Antimicrob Agents; 2014 May; 43(5):470-3. PubMed ID: 24685990
[TBL] [Abstract][Full Text] [Related]
3. Extended versus bolus infusion of meropenem and piperacillin: a pharmacokinetic analysis.
De Waele J; Carlier M; Hoste E; Depuydt P; Decruyenaere J; Wallis SC; Lipman J; Roberts JA
Minerva Anestesiol; 2014 Dec; 80(12):1302-9. PubMed ID: 24762706
[TBL] [Abstract][Full Text] [Related]
4. Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort.
Abdul-Aziz MH; Lipman J; Akova M; Bassetti M; De Waele JJ; Dimopoulos G; Dulhunty J; Kaukonen KM; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Starr T; Wallis SC; Roberts JA;
J Antimicrob Chemother; 2016 Jan; 71(1):196-207. PubMed ID: 26433783
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of meropenem and piperacillin in critically ill patients with indwelling surgical drains.
Adnan S; Li JX; Wallis SC; Rudd M; Jarrett P; Paterson DL; Lipman J; Udy AA; Roberts JA
Int J Antimicrob Agents; 2013 Jul; 42(1):90-3. PubMed ID: 23590897
[TBL] [Abstract][Full Text] [Related]
6. Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?
Udy AA; Lipman J; Jarrett P; Klein K; Wallis SC; Patel K; Kirkpatrick CM; Kruger PS; Paterson DL; Roberts MS; Roberts JA
Crit Care; 2015 Jan; 19(1):28. PubMed ID: 25632974
[TBL] [Abstract][Full Text] [Related]
7. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
Carlier M; Carrette S; Roberts JA; Stove V; Verstraete A; Hoste E; Depuydt P; Decruyenaere J; Lipman J; Wallis SC; De Waele JJ
Crit Care; 2013 May; 17(3):R84. PubMed ID: 23642005
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic drug monitoring of β-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures.
Wong G; Briscoe S; McWhinney B; Ally M; Ungerer J; Lipman J; Roberts JA
J Antimicrob Chemother; 2018 Nov; 73(11):3087-3094. PubMed ID: 30137377
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of piperacillin in critically ill patients receiving continuous venovenous haemofiltration: A randomised controlled trial of continuous infusion versus intermittent bolus administration.
Jamal JA; Roberts DM; Udy AA; Mat-Nor MB; Mohamad-Nor FS; Wallis SC; Lipman J; Roberts JA
Int J Antimicrob Agents; 2015 Jul; 46(1):39-44. PubMed ID: 25881872
[TBL] [Abstract][Full Text] [Related]
10. The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens*.
Jamal JA; Udy AA; Lipman J; Roberts JA
Crit Care Med; 2014 Jul; 42(7):1640-50. PubMed ID: 24674926
[TBL] [Abstract][Full Text] [Related]
11. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
[TBL] [Abstract][Full Text] [Related]
12. Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: effect of type of dialysis membrane on dosing requirements.
Ulldemolins M; Martín-Loeches I; Llauradó-Serra M; Fernández J; Vaquer S; Rodríguez A; Pontes C; Calvo G; Torres A; Soy D
J Antimicrob Chemother; 2016 Jun; 71(6):1651-9. PubMed ID: 26869692
[TBL] [Abstract][Full Text] [Related]
13. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study.
Roberts DM; Roberts JA; Roberts MS; Liu X; Nair P; Cole L; Lipman J; Bellomo R;
Crit Care Med; 2012 May; 40(5):1523-8. PubMed ID: 22511133
[TBL] [Abstract][Full Text] [Related]
14. Covariate determinants of effective dosing regimens for time-dependent beta-lactam antibiotics for critically ill patients.
Kaska M; Havel E; Selke-Krulichova I; Safranek P; Bezouska J; Martinkova J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2018 Sep; 162(3):219-226. PubMed ID: 29582860
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients.
Sturm AW; Allen N; Rafferty KD; Fish DN; Toschlog E; Newell M; Waibel B
Pharmacotherapy; 2014 Jan; 34(1):28-35. PubMed ID: 23864417
[TBL] [Abstract][Full Text] [Related]
16. The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study.
Shekar K; Fraser JF; Taccone FS; Welch S; Wallis SC; Mullany DV; Lipman J; Roberts JA;
Crit Care; 2014 Dec; 18(6):565. PubMed ID: 25636084
[TBL] [Abstract][Full Text] [Related]
17. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.
Roberts JA; Kirkpatrick CM; Roberts MS; Dalley AJ; Lipman J
Int J Antimicrob Agents; 2010 Feb; 35(2):156-63. PubMed ID: 20018492
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy.
Awissi DK; Beauchamp A; Hébert E; Lavigne V; Munoz DL; Lebrun G; Savoie M; Fagnan M; Amyot J; Tétreault N; Robitaille R; Varin F; Lavallée C; Pichette V; Leblanc M
Pharmacotherapy; 2015 Jun; 35(6):600-7. PubMed ID: 26095008
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience.
Richter DC; Frey O; Röhr A; Roberts JA; Köberer A; Fuchs T; Papadimas N; Heinzel-Gutenbrunner M; Brenner T; Lichtenstern C; Weigand MA; Brinkmann A
Infection; 2019 Dec; 47(6):1001-1011. PubMed ID: 31473974
[TBL] [Abstract][Full Text] [Related]
20. Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients.
Roger C; Cotta MO; Muller L; Wallis SC; Lipman J; Lefrant JY; Roberts JA
Int J Antimicrob Agents; 2017 Aug; 50(2):227-231. PubMed ID: 28689876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
